Outset Medical Reports Third Quarter 2026 Results

Higher sales and lower operating expenses narrowed the quarterly net loss, while product gross margin declined.

Rhea-AI Summary

Outset Medical (Nasdaq: OM) reported third-quarter 2026 revenue of $33.6 million, up 14% from the prior-year period. Revenue increased 6% sequentially. Console revenue rose 26% year over year to $10.5 million, while recurring revenue increased 10% to $23.1 million. Gross margin improved to 40.7% from 39.4%, although product gross margin declined to 44.2% from 45.7%.

Operating expenses fell 5% to $25.9 million. Net loss narrowed to $14.7 million, or $0.78 per share, from $17.8 million, or $1.00 per share. Non-GAAP net loss widened to $12.9 million from $12.4 million. Net cash used during the quarter was $10.3 million; cash, cash equivalents, short-term investments and restricted cash totaled $140.7 million at September 30. Outset reiterated 2026 revenue guidance of $125 million to $130 million and continues to expect full-year non-GAAP gross margin in the low-40% to mid-40% range.

15 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 10 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointQ3 console revenue reached $10.5 million, up 26% year over year and 10% sequentially.
• Moderate pointQ3 recurring revenue reached $23.1 million, up 10% year over year and 4% sequentially.
• Moderate pointQ3 operating expenses decreased 5% to $25.9 million compared with the prior-year period.
• Moderate pointQ3 operating loss narrowed to $12.269 million from $15.813 million a year earlier.
• Moderate pointQ3 net loss narrowed to $14.7 million from $17.8 million a year earlier.
• Moderate pointNine-month revenue increased to $93.094 million from $90.602 million in the prior-year period.
• Moderate pointNine-month gross margin improved to 41.9% from 38.1% in the prior-year period.
• Moderate pointNine-month net loss narrowed to $51.648 million from $62.162 million in the prior-year period.
• Moderate pointNine-month operating cash use decreased to $32.858 million from $36.806 million in the prior-year period.

6 minor points

• Minor pointQ3 gross margin increased to 40.7% from 39.4% a year earlier.
• Minor pointQ3 service and other gross profit rose to $3.210 million from $2.201 million year over year.
• Minor pointQ3 service and other gross margin increased to 32.4% from 24.8% a year earlier.
• Minor pointQ3 product gross profit increased to $10.461 million from $9.389 million a year earlier.
• Minor pointQ3 loss per share narrowed to $0.78 from $1.00 a year earlier.
• Minor point. Forward-looking: it has not happened yet and may not happen.2026 outlook remains $125 million–$130 million revenue, with expected non-GAAP gross margin in the low-40% to mid-40% range.

Negative

• Moderate pointCash, equivalents, restricted cash and investments fell to $140.7 million from $182.0 million a year earlier.
• Moderate pointQ3 net cash used totaled $10.3 million.
• Moderate pointStockholders' equity declined to $83.314 million at September 30, 2026, from $126.952 million at December 31, 2025.
• Minor pointQ3 product gross margin declined to 44.2% from 45.7% a year earlier.
• Minor pointQ3 non-GAAP net loss widened to $12.9 million from $12.4 million a year earlier.

5 minor points

• Minor pointQ3 interest income and other income, net, declined to $1.241 million from $1.855 million year over year.
• Minor pointQ3 interest expense increased to $3.505 million from $3.476 million a year earlier.
• Minor pointNine-month product revenue decreased to $64.152 million from $64.934 million in the prior-year period.
• Minor pointNine-month operating expenses increased to $83.912 million from $83.600 million in the prior-year period.
• Minor pointTerm loan balance increased to $98.368 million at September 30, 2026, from $96.237 million at December 31, 2025.

News Explained

The third-quarter report lists 18,873 thousand shares issued and outstanding at September 30, 2026, versus 18,169 thousand at December 31, 2025; the higher reported share base is the ownership denominator for common holders at quarter-end.

Key Figures

Net revenue: $33.6 million; +14% year over year Recurring revenue: $23.1 million; +10% year over year Gross margin: 40.7%; +130 basis points year over year +5 more

Net revenue

$33.6 million; +14% year over year

Third quarter 2026

Recurring revenue

$23.1 million; +10% year over year

Third quarter 2026

Gross margin

40.7%; +130 basis points year over year

Third quarter 2026

Net cash used

$10.3 million

During the quarter

Cash and investments

$140.7 million

At quarter end, including restricted cash

GAAP net loss

$14.7 million, versus $17.8 million

Third quarter 2026 versus third quarter 2025

Non-GAAP net loss

$12.9 million, versus $12.4 million

Third quarter 2026 versus third quarter 2025

2026 revenue guidance

$125 million to $130 million

Reiterated full-year guidance

Previous Earnings Reports

1 past event · Latest: Aug 06

Same Type 1 event

1. Aug 06

   Q2 earnings

   24h Move

   -5.8%

   Revenue rose 1% year over year, gross margin expanded to 42.0%, and 2026 revenue guidance was reiterated.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-gaap, gaap, stock-based compensation, restricted cash

4 terms

non-gaap financial

"On a non-GAAP basis, gross margin reached 40.8%"

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

View in glossary

gaap financial

"financial measures calculated in accordance with GAAP"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

View in glossary

stock-based compensation financial

"GAAP financial measures include stock-based compensation expense"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

View in glossary

restricted cash financial

"Total cash, including restricted cash, cash equivalents and short-term investments"

Cash that a company holds but cannot use for day-to-day operations because it is set aside for a specific purpose—such as meeting loan covenants, serving as collateral, funding an escrow, or complying with regulations. Like money in a locked savings account earmarked for a bill, restricted cash reduces the cash available to run the business and pay dividends or debts, so investors treat it differently when assessing a company’s true short-term financial strength.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN JOSE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter and Recent Highlights

• Net revenue totaled $33.6 million, an increase of 14% compared to the prior-year period and an increase of 6% sequentially.
• Console revenue of $10.5 million, an increase of 26% compared to the prior-year period and an increase of 10% sequentially.
• Recurring revenue, consisting of Tablo consumables and services, was $23.1 million, an increase of 10% compared to the prior-year period and an increase of 4% sequentially.
• Gross margin expanded to 40.7%, an increase of 130 basis points compared to the prior-year period.
• Net cash used during the quarter was $10.3 million, resulting in a total cash, cash equivalents, short-term investments and restricted cash position of $140.7 million at quarter end.
  
  

“Third-quarter results demonstrated continued progress against our strategic priorities and solid sales execution across both capital and recurring revenue,” said Leslie Trigg, Chair and Chief Executive Officer. “Consistently strong customer satisfaction and retention are expanding adoption of Tablo across our existing customer base and fueling new insourced dialysis partnerships with leading health systems. Advancing our mission to help providers nationwide improve the cost, complexity and clinical outcomes of dialysis continues to position Outset well for sustained long-term growth and value creation.”

Third Quarter 2026 Financial Results

Revenue for the third quarter was $33.6 million, an increase of 14% compared to $29.4 million in the third quarter of 2025. Product revenue of $23.7 million increased 15% from $20.6 million in the third quarter of 2025. Service and other revenue of $9.9 million increased 12% compared to $8.9 million in the third quarter of 2025. Recurring revenue from the sale of Tablo cartridges and service was $23.1 million compared to $21.1 million in the prior-year period.

Gross profit of $13.7 million increased 18% from $11.6 million in the third quarter of 2025. Gross margin was 40.7%, compared to 39.4% in the third quarter of 2025. On a non-GAAP basis, gross margin reached 40.8%, as compared to 39.9% in the third quarter of 2025. Product gross profit was $10.5 million compared to $9.4 million in the third quarter of 2025. Product gross margin was 44.2% compared to 45.7% in the third quarter of 2025. Service and other gross profit was $3.2 million, compared to $2.2 million in the third quarter of 2025. Service and other gross margin was 32.4% compared to 24.8% in the third quarter of 2025.

Operating expenses of $25.9 million decreased 5% from the same period in 2025. Research and development (R&D) expenses were $5.9 million, sales and marketing (S&M) expenses were $11.7 million, and general and administrative (G&A) expenses were $8.3 million. This compared to operating expenses of $27.4 million in the third quarter of 2025, including R&D expenses of $5.4 million, S&M expenses of $13.6 million, and G&A expenses of $8.5 million.

Excluding stock-based compensation expense and litigation charges, non-GAAP operating expenses were $24.2 million, including R&D expenses of $5.5 million, S&M expenses of $11.6 million, and G&A expenses of $7.0 million.

Net loss was $14.7 million compared to net loss of $17.8 million in the third quarter of 2025. On a non-GAAP basis, net loss was $12.9 million compared to net loss of $12.4 million in the third quarter of 2025.

Total cash, including restricted cash, cash equivalents and short-term investments, was $140.7 million as of September 30, 2026.

2026 Financial Guidance

Outset reiterated its 2026 revenue guidance of $125 million to $130 million and continues to expect non-GAAP gross margin to be in the low-40% to mid-40% range for the full year.

Conference Call Details

Outset will host a conference call today, November 4, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss third quarter results. Those interested in accessing the live or archived version of the conference call can visit the “Investors” section of the Outset Medical website at https://investors.outsetmedical.com.

Those interested in participating in the call via telephone are encouraged to register more than 15 minutes before the start of the call via the following link: https://register-conf.media-server.com/register/BIf6886fe8d04a44bbbb5a5da8650079ac. Once registered, participants will receive a dial-in number and unique PIN to join the call.

Use of Non-GAAP Financial Measures

The Company may report non-GAAP results for gross profit/loss, gross margin, operating expenses, operating margins, net income/loss, basic and diluted net income/loss per share, other income/loss, and cash flows. These non-GAAP financial measures are in addition to, and not a substitute for or superior to, financial measures calculated in accordance with GAAP. As listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release, the Company’s GAAP financial measures include stock-based compensation expense and litigation charges incurred outside of the ordinary course of business in connection with the stockholder class action and relative derivative lawsuits, as disclosed in the Company’s latest annual and quarterly reports. Stock-based compensation is a non-cash expense. In addition, litigation charges related to the above-described matters are excluded because they constitute non-routine litigation costs, arise outside of the ordinary course of the Company’s business, and are not indicative of its recurring operating results or underlying performance trends. As such, management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance and period-to-period comparisons. There are limitations related to the use of non-GAAP financial measures because they are not prepared in accordance with GAAP, may exclude significant expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in Appendix A of this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the Company’s possible or assumed future results of operations and financial position, including expectations regarding projected revenues, gross margin, operating expenses, capital expenditures, cash use, cash burn, cash position, profitability and outlook; statements about the sufficiency of the Company’s cash balances through cash-flow breakeven; statements regarding the anticipated impacts and benefits of the Company’s cost reduction actions and restructurings; statements regarding the evolution of the Company's commercial model, including changes to its sales organization and incentives, and the expected benefits thereof; statements regarding anticipated customer orders, refreshes, expansions or other business opportunities, including the expected closing, timing, size, scope and benefits thereof; statements regarding the Company’s overall business strategy, plans and objectives of management; statements regarding the anticipated launch and timing of product enhancements and new features, as well as new or expanded services, and the expected benefits, performance, and impact thereof; the Company’s expectations regarding the market sizes and growth potential for Tablo and the total addressable market opportunities for Tablo, including the potential impact of healthcare policies, programs and initiatives on patient access to and adoption of Tablo; continued execution of the Company’s initiatives designed to expand gross margins; the Company’s ability to respond to and resolve any reports, observations or other actions by the Food and Drug Administration or other regulators in a timely and effective manner; as well as the Company’s expectations regarding the impact of macroeconomic factors (including changes in tariff or trade laws and policies) on the Company, its customers and suppliers. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

About Outset Medical, Inc.

Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com.

Investor Contact

Investors@outsetmedical.com

Outset Medical, Inc. Condensed Statements of Operations (in thousands, except per share amounts) (unaudited)
		Three Months Ended										Nine Months Ended
		September 30,										September 30,
		2026					2025					2026					2025
Revenue:
Product revenue		$	23,694				$	20,558				$	64,152				$	64,934
Service and other revenue			9,902					8,873					28,942					25,668
Total revenue			33,596					29,431					93,094					90,602
Cost of revenue:
Cost of product revenue(2)			13,233					11,169					33,865					33,962
Cost of service and other revenue			6,692					6,672					20,181					22,117
Total cost of revenue			19,925					17,841					54,046					56,079
Gross profit(1)			13,671					11,590					39,048					34,523
Gross margin(1)			40.7		%			39.4		%			41.9		%			38.1		%
Operating expenses:
Research and development(2)			5,898					5,376					16,966					16,180
Sales and marketing(2)			11,736					13,550					37,167					41,482
General and administrative(2)(3)			8,306					8,477					29,779					25,938
Total operating expenses			25,940					27,403					83,912					83,600
Loss from operations			(12,269	)				(15,813	)				(44,864	)				(49,077	)
Interest income and other income, net			1,241					1,855					4,122					5,734
Interest expense			(3,505	)				(3,476	)				(10,316	)				(10,511	)
Loss on extinguishment of term loan			—					—					—					(7,685	)
Loss before provision for income taxes			(14,533	)				(17,434	)				(51,058	)				(61,539	)
Provision for income taxes			153					404					590					623
Net loss		$	(14,686	)			$	(17,838	)			$	(51,648	)			$	(62,162	)
Net loss per share, basic and diluted		$	(0.78	)			$	(1.00	)			$	(2.78	)			$	(4.37	)
Shares used in computing net loss per share, basic and diluted			18,831					17,783					18,609					14,228

(1)Gross profit and gross margin by source consisted of the following:
		Three Months Ended										Nine Months Ended
		September 30,										September 30,
		2026					2025					2026					2025
Gross profit
Product revenue		$	10,461				$	9,389				$	30,287				$	30,972
Service and other revenue			3,210					2,201					8,761					3,551
Total gross profit		$	13,671				$	11,590				$	39,048				$	34,523
Gross margin
Product revenue			44.2		%			45.7		%			47.2		%			47.7		%
Service and other revenue			32.4		%			24.8		%			30.3		%			13.8		%
Total gross margin			40.7		%			39.4		%			41.9		%			38.1		%
(2)Includes stock-based compensation expense as follows:
		Three Months Ended										Nine Months Ended
Stock-based compensation expense		September 30,										September 30,
		2026					2025					2026					2025
Cost of revenue		$	45				$	135				$	233				$	438
Research and development			363					1,117					1,777					2,426
Sales and marketing			166					1,174					1,040					2,586
General and administrative			1,114					2,654					4,787					6,103
Total stock-based compensation expense		$	1,688				$	5,080				$	7,837				$	11,553
(3)Includes non-ordinary course litigation charges related to stockholder class action and related derivative lawsuits as follows:
		Three Months Ended										Nine Months Ended
Litigation charges		September 30,										September 30,
		2026					2025					2026					2025
General and administrative		$	143					343				$	810					343
Total litigation charges		$	143					343				$	810					343

Outset Medical, Inc. Condensed Balance Sheets (in thousands, except per share amounts)
		September 30,				December 31,
		2026				2025
		(unaudited)
Assets
Current assets:
Cash and cash equivalents		$	33,942			$	35,006
Short-term investments			102,685				133,940
Accounts receivable, net			30,407				28,329
Inventories			44,989				47,609
Prepaid expenses and other current assets			4,200				5,999
Total current assets			216,223				250,883
Restricted cash			4,121				3,829
Property and equipment, net			3,541				4,670
Operating lease right-of-use assets			4,435				4,797
Finance lease right-of-use assets			1,642				—
Other assets			447				317
Total assets		$	230,409			$	264,496
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	4,292			$	554
Accrued compensation and related benefits			9,965				10,735
Accrued expenses and other current liabilities			13,349				9,433
Accrued warranty liability			1,023				1,374
Deferred revenue, current			13,468				13,795
Operating lease liabilities, current			1,755				1,739
Finance lease liabilities, current			601				—
Total current liabilities			44,453				37,630
Deferred revenue			221				406
Operating lease liabilities			2,985				3,271
Finance lease liabilities			1,068				—
Term loan			98,368				96,237
Total liabilities			147,095				137,544
Commitments and contingencies
Stockholders' equity:
Preferred Stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of September 30, 2026 and December 31, 2025			—				—
Common stock, $0.001 par value; 300,000 shares authorized as of September 30, 2026 and December 31, 2025; 18,873 and 18,169 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively			19				18
Additional paid-in capital			1,306,563				1,298,138
Accumulated other comprehensive (loss) income			(244	)			172
Accumulated deficit			(1,223,024	)			(1,171,376	)
Total stockholders' equity			83,314				126,952
Total liabilities and stockholders' equity		$	230,409			$	264,496

Outset Medical, Inc. Condensed Statements of Cash Flows (in thousands) (unaudited)
		Nine Months Ended September 30,
		2026				2025
Net cash used in operating activities		$	(32,858	)		$	(36,806	)
Net cash provided by (used in) investing activities			31,729				(106,274	)
Net cash provided by financing activities			357				55,503
Net decrease in cash, cash equivalents and restricted cash			(772	)			(87,577	)
Cash, cash equivalents and restricted cash at beginning of the period			38,835				127,343
Cash, cash equivalents and restricted cash at end of the period(1)		$	38,063			$	39,766
(1) The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed balance sheets that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands):
		September 30,
		2026				2025
Cash and cash equivalents		$	33,942			$	36,437
Restricted cash			4,121				3,329
Total cash, cash equivalents and restricted cash*		$	38,063			$	39,766
* The total cash, including restricted cash, cash equivalents and investment securities as of September 30, 2026 was $140.7 million; compared to $182.0 million as of September 30, 2025.

Appendix A

Outset Medical, Inc. Results of Operations – Non-GAAP (in thousands, except per share amounts) (unaudited)
Reconciliation between GAAP and non-GAAP net loss per share:
		Three Months Ended										Nine Months Ended
		September 30,										September 30,
		2026					2025					2026					2025
GAAP net loss per share, diluted		$	(0.78	)			$	(1.00	)			$	(2.78	)			$	(4.37	)
Stock-based compensation expense			0.09					0.29					0.42					0.81
Litigation charges			0.01					0.02					0.04					0.02
Non-GAAP net loss per share, diluted		$	(0.68	)			$	(0.69	)			$	(2.32	)			$	(3.54	)
Reconciliation between GAAP and non-GAAP net loss:
		Three Months Ended										Nine Months Ended
		September 30,										September 30,
		2026					2025					2026					2025
GAAP net loss, diluted		$	(14,686	)			$	(17,838	)			$	(51,648	)			$	(62,162	)
Stock-based compensation expense			1,688					5,080					7,837					11,553
Litigation charges			143					343					810					343
Non-GAAP net loss, diluted		$	(12,855	)			$	(12,415	)			$	(43,001	)			$	(50,266	)
Reconciliation between GAAP and non-GAAP results of operations:
		Three Months Ended										Nine Months Ended
		September 30,										September 30,
		2026					2025					2026					2025
GAAP gross profit		$	13,671				$	11,590				$	39,048				$	34,523
Stock-based compensation expense			45					135					233					438
Non-GAAP gross profit		$	13,716				$	11,725				$	39,281				$	34,961
GAAP gross margin			40.7		%			39.4		%			41.9		%			38.1		%
Stock-based compensation expense			0.1					0.5					0.3					0.5
Non-GAAP gross margin			40.8		%			39.9		%			42.2		%			38.6		%
GAAP research and development expense		$	5,898				$	5,376				$	16,966				$	16,180
Stock-based compensation expense			(363	)				(1,117	)				(1,777	)				(2,426	)
Non-GAAP research and development expense		$	5,535				$	4,259				$	15,189				$	13,754
GAAP sales and marketing expense		$	11,736				$	13,550				$	37,167				$	41,482
Stock-based compensation expense			(166	)				(1,174	)				(1,040	)				(2,586	)
Non-GAAP sales and marketing expense		$	11,570				$	12,376				$	36,127				$	38,896
GAAP general and administrative expense		$	8,306				$	8,477				$	29,779				$	25,938
Stock-based compensation expense			(1,114	)				(2,654	)				(4,787	)				(6,103	)
Litigation charges			(143	)				(343	)				(810	)				(343	)
Non-GAAP general and administrative expense		$	7,049				$	5,480				$	24,182				$	19,492
GAAP total operating expense		$	25,940				$	27,403				$	83,912				$	83,600
Stock-based compensation expense			(1,643	)				(4,945	)				(7,604	)				(11,115	)
Litigation charges			(143	)				(343	)				(810	)				(343	)
Non-GAAP total operating expense		$	24,154				$	22,115				$	75,498				$	72,142

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Outset Medical's third-quarter 2026 revenue and earnings results?

Outset Medical reported $33.6 million in revenue and a $14.7 million net loss for the quarter ended September 30, 2026. Revenue increased 14% year over year and 6% sequentially. Loss per share was $0.78, compared with $1.00 in the prior-year quarter.

What is Outset Medical's 2026 financial guidance?

Outset Medical reiterated 2026 revenue guidance of $125 million to $130 million. The company continues to expect full-year non-GAAP gross margin in the low-40% to mid-40% range.